According to current guidelines, what is the recommended dual antiplatelet therapy (DAPT) for a patient with non‑ST‑segment elevation myocardial infarction (NSTEMI) that progresses to acute myocardial infarction (AMI)?

DAPT for NSTEMI Progressing to AMI

For NSTEMI patients (which is already a form of AMI), aspirin plus a P2Y12 inhibitor should be initiated immediately, with ticagrelor (180 mg loading dose, then 90 mg twice daily) or prasugrel (60 mg loading dose, then 10 mg daily) preferred over clopidogrel, and continued for at least 12 months. 1, 2

Clarification on Terminology

NSTEMI is an acute myocardial infarction—it doesn't "progress to AMI." The question likely refers to NSTEMI management or possibly NSTEMI that evolves to STEMI, but the DAPT approach remains fundamentally the same across the acute coronary syndrome spectrum.

Initial DAPT Strategy

Aspirin Component

• Loading dose: 150-300 mg orally (or 75-250 mg IV) 1
• Maintenance dose: 75-100 mg daily (preferably 81 mg) indefinitely 1, 2

P2Y12 Inhibitor Selection (in order of preference)

For patients undergoing PCI:

1. Prasugrel should be considered in preference to ticagrelor for NSTEMI patients proceeding to PCI 1

   • Loading: 60 mg
   • Maintenance: 10 mg daily (5 mg if age ≥75 years or weight <60 kg)
   • Contraindications: Prior stroke/TIA, active bleeding 3, 4

2. Ticagrelor (alternative first-line option)

   • Loading: 180 mg
   • Maintenance: 90 mg twice daily
   • Can be used regardless of invasive vs. conservative strategy 1

3. Clopidogrel (only when prasugrel or ticagrelor unavailable, not tolerated, or contraindicated)

   • Loading: 300-600 mg
   • Maintenance: 75 mg daily 1

Duration of Therapy

Standard duration: 12 months for all patients with ACS, regardless of stent type (BMS or DES) 3, 1, 2

Early discontinuation considerations:

• If bleeding risk outweighs ischemic benefit, earlier discontinuation should be considered 3, 1
• High bleeding risk (HBR) patients: Consider abbreviated DAPT (as short as 1 month) followed by P2Y12 inhibitor monotherapy 1

Extended duration (>12 months):

• May be reasonable in high ischemic risk patients without increased bleeding risk 1
• Class IIb recommendation for continuation beyond 12 months 3, 5

Critical Pitfalls to Avoid

Age-Related Considerations

• Prasugrel in patients ≥75 years: Generally not recommended due to increased fatal/intracranial bleeding risk, except in high-risk situations (diabetes, prior MI) where 5 mg dose may be considered 3, 4

Weight-Based Adjustments

• Patients <60 kg on prasugrel: Reduce maintenance dose to 5 mg daily due to increased bleeding risk 3, 4

Stroke History

• Absolute contraindication: Never use prasugrel in patients with prior stroke or TIA—this causes net harm 3, 4

Pre-treatment Timing

• Routine pre-treatment NOT recommended when coronary anatomy is unknown and early invasive management is planned 1
• Exception: May consider pre-treatment if invasive strategy delayed >24 hours 2

Special Populations

Medical Management Without PCI

• Aspirin indefinitely plus clopidogrel or ticagrelor for up to 12 months 3

Planned CABG

• Discontinuation periods before surgery:
  • Clopidogrel: ≥5 days 3, 6
  • Prasugrel: ≥7 days 3, 6
  • Ticagrelor: ≥5 days 3, 6
• Continue aspirin perioperatively 3, 6

High Bleeding Risk Patients

The most recent 2025 ACC/AHA guidelines 2 emphasize bleeding risk reduction strategies:

• Proton pump inhibitor for GI bleeding risk
• Transition to ticagrelor monotherapy ≥1 month post-PCI (after tolerating DAPT)
• Consider DAPT abbreviation in HBR patients 1

Evidence Strength

The 2020 ESC guidelines 1 provide the most recent comprehensive recommendations (Class I, Level A-B evidence), with the 2025 ACC/AHA guidelines 2 reinforcing these approaches. The preference for prasugrel over ticagrelor in PCI-treated NSTEMI patients represents a Class IIa recommendation based on the ISAR-REACT 5 trial. Both are superior to clopidogrel for reducing ischemic events, though at the cost of increased bleeding compared to clopidogrel 1, 5.